Journal of dermatological science
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Ustekinumab has been evaluated in Caucasian patients with psoriasis, but no studies have been conducted in Asian patients. ⋯ Treatment with subcutaneous ustekinumab 45mg offers a favorable benefit/risk profile for Taiwanese and Korean patients with moderate-to-severe psoriasis. The efficacy and safety profile is consistent with the global phase III studies of ustekinumab in psoriasis.